Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial

A H Gershlick; D Spriggins; S W Davies; Y D Syndercombe Court; J Timmins; A D Timmis; M T Rothman; C Layton; R Balcon

doi:10.1136/hrt.71.1.7

Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial

A H Gershlick, D Spriggins, S W Davies, Y D Syndercombe Court, J Timmins, A D Timmis, M T Rothman, C Layton, R Balcon

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in treated and placebo groups.

Original language	English
Pages (from-to)	7-15
Number of pages	9
Journal	British Heart Journal
Volume	71
Issue number	1
DOIs	https://doi.org/10.1136/hrt.71.1.7
Publication status	Published - 1994

Access to Document

10.1136/hrt.71.1.7

Cite this

Gershlick, A. H., Spriggins, D., Davies, S. W., Syndercombe Court, Y. D., Timmins, J., Timmis, A. D., Rothman, M. T., Layton, C., & Balcon, R. (1994). Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. British Heart Journal, 71(1), 7-15. https://doi.org/10.1136/hrt.71.1.7

@article{c4fa53fa5679401a8232633b94dacc04,

title = "Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial",

abstract = "To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in treated and placebo groups.",

author = "Gershlick, {A H} and D Spriggins and Davies, {S W} and {Syndercombe Court}, {Y D} and J Timmins and Timmis, {A D} and Rothman, {M T} and C Layton and R Balcon",

year = "1994",

doi = "10.1136/hrt.71.1.7",

language = "English",

volume = "71",

pages = "7--15",

journal = "British Heart Journal",

issn = "0007-0769",

publisher = "BMJ Publishing Group",

number = "1",

}

Gershlick, AH, Spriggins, D, Davies, SW , Syndercombe Court, YD, Timmins, J, Timmis, AD, Rothman, MT, Layton, C & Balcon, R 1994, 'Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial', British Heart Journal, vol. 71, no. 1, pp. 7-15. https://doi.org/10.1136/hrt.71.1.7

TY - JOUR

T1 - Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty

T2 - results of a randomised placebo controlled trial

AU - Gershlick, A H

AU - Spriggins, D

AU - Davies, S W

AU - Syndercombe Court, Y D

AU - Timmins, J

AU - Timmis, A D

AU - Rothman, M T

AU - Layton, C

AU - Balcon, R

PY - 1994

Y1 - 1994

N2 - To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in treated and placebo groups.

AB - To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in treated and placebo groups.

U2 - 10.1136/hrt.71.1.7

DO - 10.1136/hrt.71.1.7

M3 - Article

C2 - 8297699

SN - 0007-0769

VL - 71

SP - 7

EP - 15

JO - British Heart Journal

JF - British Heart Journal

IS - 1

ER -

Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial

Abstract

Access to Document

Fingerprint

Cite this